Understand the source comparison
Peptides for Leaky Gut Syndrome Protocol Evidence Guide: Method Comparison
BPC-157 Tight junction stabilisation via VEGF upregulation and occludin expression 250–500mcg daily subcutaneous or oral 2–4 weeks for permeability reduction Preclinical rodent models; limited human data Strongest evidence for direct mucosal repair; fast-actin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Tight junction stabilisation via VEGF upregulation and occludin expression
- 250–500mcg daily subcutaneous or oral
- 2–4 weeks for permeability reduction
- Preclinical rodent models; limited human data
- Strongest evidence for direct mucosal repair; fast-acting but requires consistent dosing
- Thymosin Alpha-1
- Immune modulation in GALT; Treg expansion and cytokine suppression
- 1.6–3.2mg twice weekly subcutaneous
- 4–8 weeks for inflammatory marker reduction
- Phase 2 trials in hepatitis/cancer; extrapolated for gut use
- Best for immune-driven permeability; slower onset but addresses root inflammatory driver
- KPV Tripeptide
- Alpha-MSH-derived anti-inflammatory signaling in colonic mucosa
- 500mcg 2–3x daily oral or subcutaneous
- 3–6 weeks for symptom and biomarker improvement
- Small human pilot studies in IBD
- Promising oral bioavailability; less data than BPC-157 but non-invasive delivery
- TB-500 (Thymosin Beta-4)
- Actin regulation and epithelial migration during wound healing
- 2–5mg weekly subcutaneous
- 4–6 weeks for tissue regeneration
- Preclinical wound healing models; minimal gut-specific research
- Indirect benefit through general tissue repair; less targeted than BPC-157
- The table shows that no single peptide addresses every contributor to increased intestinal permeability. BPC-157 excels at rapid tight junction repair but doesn't resolve underlying immune dysregulation. Thymosin alpha-1 modulates chronic inflammation but takes longer to produce measurable barrier improvements. Combination protocols. BPC-157 for acute repair alongside thymosin alpha-1 for immune correction. Reflect how research teams approach complex barrier dysfunction rather than single-agent interventions.